Innovation

October 18-19, 2016San Francisco

15TH ANNUAL

The BIO Investor Forum is an international biotech investor conference focused on investment trends and op-portunities in life sciences, with unbiased emphasis on venture-stage growth and emerging public companies as well as those poised to join the growth “watch list” in 2017.

Why Investors AttendHEAR from and meet with executives at the top life sciences growth companies.

EVALUATE fresh investment opportunities including compatible, complementary and competitive companies.

BENEFIT from candid panel discussions with leading clinical experts and investigators with insights on pipeline research and clinical practice.

GET A ‘BIG PICTURE’ OVERVIEW of the industry and the issues affecting product innovation, capitalization, and commercialization.

Why Companies Attend MEET one-on-one with new and current investors, analysts, and partnering companies.

GET THE PULSE on the latest life sciences investment trends from sophisticated investment and company executives.

SHOWCASE your company story in presentations to qualified investors.

NETWORK with peers, investors and potential partners.

-1-

900+ attendees 1,700+ partnering meetings scheduled

175 private and public company presentations 295 partnering companies

-2-

2016 Advisory CommitteeScott C. Brun, MD,Vice President, Corporate Strategy Office Head, AbbVie Ventures

Detlev BiniszkiewiczChief Executive Officer & President, Surface Oncology

Julia C. Owens, PhDPresident and Chief Executive Officer, Millendo Therapeutics

Camille D. SamuelsPartner, Venrock

Jeremy SpringhornPartner, Corporate Development, Flagship Ventures

Asish K. Xavier, PhDVice President, Venture Investments, Johnson & Johnson Innovation – JJDC, Inc.

KC StoneManaging Director, Head of Healthcare Investment Banking, BTIG

Rajeev Dadoo, PhDPartner, S.R. One, Limited

David H. Donabedian, PhDVenture Partner, Longwood Fund

Charlotte Hubbert, PhDPartner, Gates Foundation Venture Capital

Michael KingManaging Director and Senior Research Analyst, JMP Securities

John ChambersVice-Chairman and Head of Healthcare Investment Banking, ROTH Capital Partners

Carole NuechterleinHead, Roche Venture Fund

Jennifer Landress, CMPSenior Vice President and Chief Operating Officer, Biocom

Brian HagertySenior Director, Head of Healthcare Capital Markets, New York Stock Exchange

Sara RadcliffePresident & CEO, California Life Sciences Association (CLSA)

Matthew Roden, PhDVice President and Head of Strategic Corporate Development, Bristol-Myers Squibb

Brian LeuthnerCo-Founder, President and Chief Executive Officer, Edge Therapeutics, Inc.

Michael MirskyManaging Director, Investment Banking, H.C. Wainwright & Co., LLC

Blaine McKee, PhDHead of Transactions and Interim Head of Corporate Development, Shire

-3-

Program

Monday, October 17, 201612:00 PM - 1:00 PM SPARK Registration

1:00 PM - 5:00 PM BIF Registration

1:00 PM - 5:00 PM Partnering Desk

1:00 PM - 5:30 PM SPARK Program

5:30 PM - 6:30 PM SPARK Reception

Tuesday, October 18, 20166:30 AM - 5:30 PM Partnering Desk

6:30 AM - 5:00 PM Registration 

7:00 AM - 7:55 AM Networking Breakfast 

7:15 AM - 5:30 PM Satellite Partnering Desk

7:30 AM - 5:30 PM Partnering Meetings

8:00 AM - 5:25 PM Company Presentations

7:30 AM - 5:30 PM Partnering Hospitality Suites

9:00 AM - 10:15 AM The Intersection of Inflammation and Immu-no-Oncology: Risks and Opportunities

10:00 AM - 10:30 AM Mid-Morning Coffee Service

11:00 AM - 11:55 AM Policy Outlook—PDUFA VI: What Changes to Expect, plus Congressional Action Update

12:00 PM - 1:25 PM Opening Plenary Lunch

Fireside Chat: Ryan Watts, PhD, Chief Executive Offi-cer, Denali Therapeutics

2:00 PM - 2:55 PM Implications of Large-Cap Pharma M&A Trends on Biotechs: Rising or Falling Deal Volume?

3:00 PM - 3:30 PM Mid-Afternoon Coffee Service

3:00 PM - 3:55 PM View from the Board: What Do Private Company Inves-tors and Outside Directors Want from Their CEOs?

4:30 PM - 5:30 PM Translating Microbiome Research into Treatments

5:30 PM - 6:30 PM Welcome Reception

Wednesday, October 19, 20167:00 AM - 7:55 AM Networking Breakfast

7:00 AM - 4:30 PM Registration

7:15 AM - 5:00 PM Satellite Partnering Desk

7:30 AM - 4:30 PM Partnering Meetings

7:00 AM - 5:00 PM Partnering Desk

8:00 AM - 3:55 PM Company Presentations

8:00 AM - 4:30 PM Partnering Hospitality Suites

9:00 AM - 9:55 AM Reversing the Crossover Flow: Venture Fund Invest-ments in Public Companies (presented by BioCentury)

10:00 AM - 10:30 AM Mid-Morning Coffee Service

10:00 AM - 10:55 AM Fireside Chat: Liam Rat-cliffe, MD, PhD, Managing Director, New Leaf Venture Partners

11:00 AM - 11:55 AM Benefiting from Innovative Clinical Trial Designs: Bio-markers, Patient-Oriented Endpoints, Batch Trials, and Digital Tools

12:00 PM - 1:25 PM Plenary Lunch

Fireside Chat: Rachel Haur-witz, PhD, CEO, Caribou Biosciences, Inc.

2:00 PM - 2:55 PM Small Biotechs Licensing Assets to Develop from Large-Cap Pharma

Elizabethan Room

3:00 PM - 3:30 PM Mid-Afternoon Coffee Service

3:00 PM - 3:55 PM Gene Therapy: Navigating Towards Approvals

4:00 PM - 5:00 PM Market Outlook—Post-Elec-tion Scenarios and Funding Alternatives in a Tepid IPO Climate

5:00 PM - 6:00 PM Closing Happy Hour

The BIO SPARK Showcase Event provides an excellent opportunity for academic researchers in the SPARK network to showcase drug development programs that are ready for partnering or venture funding. The symposium will feature a dozen presentations from a mix of international, translational research start-ups.

AT STANFORD

SPARK

-4-

Therapeutic PanelsThe Intersection of Inflammation and Immuno-Oncology: Risks and OpportunitiesThe success of checkpoint inhibitors for particular cancers, such as melanoma, has inspired extensive research into combination therapies and pursuit of extra indications, including treating inflammatory diseases. However, when immuno-oncology treatments run into trial-stopping problems, those setbacks often involve cytokine release syndrome issues caused by too much inflammation.  What do we need to know about this intersection to guide research and investment prioritization in this terrain?

Moderator: Michael King, Managing Director and Senior Research Analyst, JMP SecuritiesSpeakers:

• Paul Biondi, Senior Vice President, Head of Business Development, Bristol-Myers Squibb• Pablo Cagnoni, MD, President and Chief Executive Officer, Tizona Therapeutics, Inc.• Mitchell H. Gold, MD, Executive Chairman & Acting CEO, Alpine Immune Sciences • Shawn Iadonato, PhD, Chief Executive Officer, Kineta, Inc.• Alex Szidon, PhD, Executive Director, Business Development & Licensing; Head, West Coast Innovation Hub,

Merck and Co., Inc.

Translating Microbiome Research into TreatmentsRecent years have seen a lot of excitement in the microbiome space, with the intention of bringing new microbiome-derived drugs and therapies to the market.  As more collaborations get underway and investment grows in the space, including the $121M National Microbiome Initiative commitment from the White House, we can anticipate that this space will garner more attention as biopharma develops new approaches and advances candidates further into the clinic.  However, getting microbiome-inspired candidates to become commercially viable therapeutics presents a number of challenges, including uncertainties in drug development and questions about intellectual property and regulatory pathways.  This panel will feature discussions about current experiences in microbiome drug development and the promising future of microbiome therapies.

Moderator: Andres Hurtado-Lorenzo, PhD, Director of Translational Research, Crohn’s and Colitis Foundation of AmericaSpeakers:

• Nick Conley, PhD, Co-founder and Chief Executive Officer, EpiBiome• Colleen Cutcliffe, PhD, Co-founder and Chief Executive Officer, Whole Biome• Glenn Nedwin, PhD, MoT, Chief Executive Officer and President, Second Genome, Inc.

 

-5-

Therapeutic Panels

Benefiting from Innovative Clinical Trial Designs: Biomarkers, Patient-Oriented Endpoints, Batch Trials, and Digital ToolsRecent analyses from BIO and from McKinsey & Company suggest higher clinical trial success rates related to use of selection biomarkers and from trial collaborations.  Traditional outcome measures are being reconsidered, by trial sponsors and regulators, to impact drug development in ways that can help patients faster while digital tools, such as Apple’s ResearchKit, hold promise for cheaper, bigger trials.  This panel will showcase some of the latest approaches currently being used to increase success and improve productivity in clinical development.

Moderator: Komathi Stem, ReThynk Consulting Speakers:

• Sanjay Kakkar, MD, MSC, MPH, Chief Executive Officer, Armetheon• Melissa C. Paoloni, DVM, DACVIM-O, Executive Director of Clinical Trials, QuantumLeap Healthcare Collaborative

(I-SPY trials)• Aidan Power, MB, BCh, Msc, MRCPsych, Vice President of Program and Portfolio Management, Alzheon, Inc.• Beth Rogozinski, Chief Product Officer, Pear Therapeutics• David Thomas, CFA, Senior Director, Industry Research and Policy Analysis, BIO

Gene Therapy: Navigating Towards ApprovalsEnthusiasm for gene therapy continues to be strong as indicated by recent IPOs and the FDA granting breakthrough status for multiple candidates in this space.  However, as gene therapies get closer to commercialization in the U.S., often stunning with remarkable clinical results for specific patient populations, legitimate questions arise concerning the scalability of their treatments and the valuation models to deliver economically sustainable therapeutics.  This panel will discuss the current gene therapy landscape, including present market environments and investment opportunities, and how biopharma is addressing the challenges to commercialization.

Moderator: Birgitt Schuele, MD, Associate Professor and Director of Gene Discovery and Stem Cell Modeling, Parkinson’s InstituteSpeakers:

• Louis Breton, Chief Executive Officer and Director, Calimmune, Inc.• Scott Clarke, Senior Vice President, Product Development, BioMarin Pharmaceutical Inc. • Sandy Macrae, MB, ChB, PhD, President and Chief Executive Officer, Sangamo Bioscences, Inc.• Carole Nuechterlein, Head, Roche Venture Fund

(Speakers added daily. Please visit www.bio.org/investorforum for most up to date program and confirmed presenters).

-6-

Therapeutic Panels

Policy Outlook—PDUFA VI: What Changes to Expect, plus Congressional Action UpdateThe Prescription Drug User Fee Act (PDUFA) comes up for its five-year reauthorization by the U.S. Congress next year with negotiations over adjustments going on already.  This act sets the terms for the major economic model for drug developer/FDA relationships.  In addition, unresolved proposals for Zika-response funding, 21st Century Cures, IP reform, antibiotic resistance research, the TPP, and CMS reimbursements may take dramatic twists related to the election cycle, with implications on biopharma budget plans and company valuations. Hear from BIO experts and others close to the policy process.

Moderator: Cartier Esham, PhD, Executive Vice President for Emerging Companies, BIOSpeakers: 

• Elona Baum, Managing Director, DEFTA Partners• John Glasspool, Executive Vice President, Head of Corporate Strategy and Customer Operations at

Baxalta US, Shire• Elizabeth Krutoholow, Senior Analyst, Bloomberg Intelligence 

-7-

Business Development Panels

 Implications of Large-Cap Pharma M&A Trends on Biotechs: Rising or Falling Deal Volume?2015 was a vibrant year for biopharma M&A, with nearly $170B in total deals closed. This year has also seen its fair share of large deals in the headlines, and activity may continue as companies try to remain competitive at scale. These mergers typically shed valuable talent that both biotechs and investors look to hire. However, recent stock market conditions suggest a rebalancing between deal premiums and IPO fundraising expectations. Learn from a panel of M&A experts whether deal fatigue exists now, and what larger trend changes they foresee for large-cap pharmas, small to mid-size biotechs, and investors.

Moderator: Matthew K. Hudes, Chief Executive Officer, bdlBiologxSpeaker:

• Scott Brun, MD, Vice President, Corporate Strategy Office Head, AbbVie Ventures• Clare O’Brien, Partner, Shearman & Sterling LLP• David Parrot, Managing Director, Head of Life Sciences Investment Banking, SunTrust Robinson Humphrey• Matthew Roden, PhD, Vice President and Head of Strategic Corporate Development, Bristol-Myers Squibb• Marc Schneidman, Founder, Chief Investment Officer and Managing Member, Aquilo Capital

View from the Board: What Do Private Company Investors and Outside Directors Want from Their CEOs?More than half of biotech CEOs are first-time CEOs; as such, many have less experience with engagement of a Board and the growth challenges of private companies than most of their investors.  Building these critical relationships and leveraging the cumulative experience of the Board can greatly increase a company’s success and ability to navigate obstacles.  This panel of experienced outside directors will discuss best practices for effective CEO-board relationships and give CEOs insight into the expectations from their Board.

Moderator: Michael J. O’Donnell, Partner, Morrison & Foerster LLPSpeakers:

• David Donabedian, PhD, Partner, Longwood Ventures• Elaine J. Heron, PhD, Director, BioMarin Pharmaceutical Inc; Chair and former CEO, Amplyx Pharmaceuticals, Inc.• Charlotte Hubbert, PhD, Partner, Gates Foundation Venture Capital• Nina Kjellson, General Partner, Canaan Partners• Camille Samuels, Partner, Venrock

Reversing the Crossover Flow: Venture Fund Investments in Public Companies (presented by BioCentury)While 2015 was marked by a surge of public investors dipping into private biotechs, the flow of capital in 2016 is dramatically different. Crossover-backed IPOs are few and far between and the follow-on market is highly selective. Amid this backdrop, private investments in public equities (PIPEs) are accelerating as an option for biotechs seeking capital, with 64 such deals in Q2 2016, according to data assembled by BioCentury. A closer look at the PIPE data reveals that multiple traditional venture funds are participating, either to support existing portfolio companies or because they are finding public companies with valuations on par with early stage private biotechs. This panel will delve into venture funds that are increasingly looking to the public markets, including the types of financings they prefer and whether it will lead to a capital crunch for some types of private companies.

-8-

Business Development Panels

Moderator: Steve Edelson, Senior Editor, Finance,  BioCentury Publications Inc.Speakers:

• Allyson Rinderle, Vice President, Longitude Capital• Mahendra G. Shah, PhD, Managing Director, Vivo Capital• Kurt Von Emster, Managing Partner, Abingworth

Small Biotechs Licensing Assets to Develop from Large-Cap PharmaChanges in corporate portfolio strategy or trial design complications can land promising drug candidates on the shelf—often with no plans to return to the clinic.  This past year has seen an uptick of deals in which biotechs have taken “unwanted” assets from large companies to advance into development.  Companies making these bets are looking for opportunities to repurpose these candidates, either through new clinical targets or to reduce toxicity or increase efficacy.  Hear from deal-making experts and from biotech executives attempting to shepherd these candidates toward approval and with higher ROI than the first owners. 

Moderator: Effie Toshav, Partner, Fenwick & West LLPSpeakers:

• James McArthur, PhD, Chief Executive Officer, Imara; Founder & Chief Scientific Officer, Cydan Development, Inc.

• Michael A. Metzger, President and Chief Operating Officer, Syndax Pharmaceuticals, Inc.• Julia C. Owens, PhD, President & Chief Executive Officer, Millendo Therapeutics• Asish K. Xavier, PhD, Vice President, Venture Investments, Johnson & Johnson Innovation–JJDC, Inc.

 Market Outlook—Post-Election Scenarios and Funding Alternatives in a Tepid IPO ClimateThe 2016 U.S. presidential campaigns have generated notable discussion regarding valuation of medicines, as well as numerous healthcare policy suggestions from candidates and industry players alike. This recent attention correlates with a slowdown in stock market returns to biotech. As we near Election Day, uncertainty abounds—how will the biotech sector be affected by a new President’s healthcare agenda? Meanwhile, global licensing, M&A, and other deal activity remain robust despite a tepid IPO climate. A diverse panel of experts will discuss what we might expect in the coming year, as companies seek the capital to grow.

Moderator: Elizabeth Krutoholow, Senior Analyst, Bloomberg IntelligenceSpeakers:

• John Chambers, Vice-Chairman and Head of Healthcare Investment Banking, ROTH Capital Partners• Brian Hagerty, Senior Director, New York Stock Exchange• Brian Leuthner, Co-Founder, President and Chief Executive Officer, Edge Therapeutics, Inc.• Wendye Robbins, MD, President and Chief Executive Officer, Blade Therapeutics

-9-

Fireside Chats

 Rachel Haurwitz, PhD, President and Chief Executive Officer, Caribou Biosciences, Inc.October 19, 2016 12:00 p.m. - 1:25 p.m.Moderator: David Schechner, Managing Director and Head of Life Sciences, Baird

Liam Ratcliffe, MD, PhD, Managing Director, New Leaf Venture PartnersOctober 19, 2016 10:00 a.m. - 10:55 a.m. Moderator: K.C. Stone, Managing Director, Head of Healthcare Investment Banking, BTIG

Ryan Watts, PhD, Chief Executive Officer, Denali Therapeutics Inc.October 18, 2016 12:00 p.m. - 1:25 p.m. Moderator: Andrew Fein, Managing Director and Senior Healthcare Analyst, Research Division, H.C. Wainwright & Co., LLC

-10-

Participating Investors

2M Companies, Inc.5AM Ventures5Lights, LLCAbbVie Inc.AbingworthAccelerator CorporationAlexandria Venture InvestmentsAlly Bridge GroupAME Cloud VenturesAquilo Capital Management LLC.ARCH Venture PartnersAristides CapitalArix BioscienceArtisan PartnersAsahi Kasei AmericaAstellas Venture Management LLCAT Technology, Inc.ATEM CapitalAthyrium Capital Management, LP.BailardBay City Capital LLCBGI VentureBill & Melinda Gates FoundationBiomark CapitalBioPacific InvestorsBoson Capital LLCBrace Pharma CapitalBracknor Investment GroupBridge BankBridgeBioBTIGBurrage Capital ManagementCanaan PartnersCato BioVenturesCedrus Investments LtdCenova CH Innovations LLC Chardan Capital Markets, LLCCleveland ClinicCodon CapitalColorado Institute for Drug, Device and

Diagnostic DevelopmentConcord Venture Capital GroupCSC Leasing CompanyDeerfield ManagementDEFTA Partners

Delphi VenturesDiscover Fund Management, LLLPDorset Capital LLCEGB Advisors, LLCEleven Two CapitalEmerson CollectiveFapon CapitalFinance Technology Leverage LLCFirst Republic BankFirst Republic Investment ManagementFirst Republic WealthFrazier Healthcare PartnersFrontline BioVenturesGenesys CapitalGolden SeedsHamilton LaneHealthCare Royalty PartnersIllumina VenturesInbio VenturesInventis Investment Holdings (China) LtdiQX Ltd Biotechnology Investment

CompanyJAFCO Life Science InvestmentJDRF Diabetes FoundationJohnson & Johnson Innovation - JJDCJump CapitalKatan Family OfficeKingsford Capital ManagementLife Science AngelsLincoln Park CapitalLongitude CapitalLYFE CapitalMallinckrodt PharmaceuticalsMBL Venture Capital Co., Ltd.MedImmune VenturesMission Bay CapitalMitsui & Co. Global Investment, Inc.Moore Venture Partners, LP.MP Healthcare Venture Management, Inc.MPM Capital, Inc.NanoDimension Management LimitedNew Enterprise Associates (NEA)New Leaf Venture PartnersNGN CapitalNomura SecuritiesNovaQuest Capital Management

NovaQuest Private EquityNovo A/SNWQ Investment Management Company,

LLCOceanIQ CapitalOpus Point PartnersOra, Inc.OrbiMed Advisors LLCOresund CapitalOxford Finance, LLCPalo Alto Investors, LLCPrevail Partners, LLCRBV Capital (RBV LP) Remiges VenturesRosetta Capital LimitedSanten Pharmaceutical Co., Ltd.SDL VenturesSilverCreek PartnersSK Telecom Americas InnopartnersSofinnova VenturesSR OneSunTrust Robinson HumphreySyno CapitalTaiAn Technologies Corp.Taiho Ventures, LLCTakeda Ventures, Inc.TEEC Angel FundThe Sirona Fund LLCToronto Stock ExchangeTosoh CorporationTPG (owned by Tarrant Capital IP, LLC.)TSX Venture ExchangeTVM Capital GroupVersant Venture Management, LLC. Vincera CapitalVistus Inspire VenturesVivo CapitalWellington Financial LPWRF Capital (Washington Research

Foundation)Xeraya Capital Life VentureYorkville Advisors Global

Below is the preliminary list of participating investors for the 2016 BIO Investor Forum.

-11-

Presenting Companies

The following is the list of presenting companies for the 15th Annual BIO Investor Forum. Presenters will consist of Discovery Companies (under $25M raised to date in Seed or Series A financing rounds), established private companies (over $25M raised and in Series B and above) and emerging public companies.

CARDIOVASCULARRubicon Biotechnology

CNS/NEUROLOgICALAphios CorporationBioAxone BioSciencesBioVerity Inc.Cerecor, Inc (NASDAQ: CERC)DRI Biosciences CorporationEmbera NeuroTherapeutics, Inc.Mitochon Pharmaceuticals, Inc.Origenis GmbHProbiodrug AG (Euronext, Amsterdam:

PBD)Pulse Therapeutics, Inc.Relmada Therapeutics (OTCQB: RLMD)Reviva Pharmaceuticals Inc.Selonterra LLC

DERMATOLOgYDermala Inc.Edesa Biotech Inc.Phi Therapeutics, Inc.PuriCore, Inc. (AIM: PURI-L)

DIAGNOSTICS3i Diagnostics, Inc. Avisa Pharma Inc.BioMarker Strategies, LLCCelcuity LLCCuretis N.V. (Euronext Amsterdam

and Brussels: CURE)Liquid Biotech USA, Inc.Novodiax IncOncocyte (NYSE: OCX)ProLungdxSageMedic, Inc. TAI Diagnostics Inc.Trovagene, Inc. (NASDAQ: TROV)

DIgITAL HEALTHElemeno Health, Inc.

DRUG DELIVERYEos Biosciences, Inc.Vali Nanomedical Corporation

GASTROINTESTINALRedHill Biopharma Ltd. (NASDAQ /

TASE: RDHL)Synthetic Biologics, Inc (NYSE MKT:

SYN)

GENE/CELL THERAPYArgos Therapeutics, Inc. (NASDAQ:

ARGS)OncoSec Medical Incorporated (NASDAQ:

ONCS)

IMMUNOLOgYAbreos BiosciencesAurinia Pharmaceuticals (AUPH: AUP)

Exicure iNC.Heat Biologics, Inc. (NASDAQ: HTBX)KPI Therapeutics

INFECTIOUS DISEASESAmplyx PharmaceuticalsMicreosPrEP Biopharm LimitedSequella, Inc.Trilogy TherapeuticsValley Fever Solutions

INFLAMMATIONNoveome Therapeutics

MEDICAL DEVICESAethlon Medical, Inc. (NASDAQ: AEMD)Arch Therapeutics, Inc. (OTCQB: ARTH)Corvida MedicalCytoSorbents (NASDAQ: CTSO)Volumetric Inc.

METABOLIC DISEASESAptamiR Therapeutics, Inc.CohBar (TSXV and OTCQX: COB.U and

CWBR)Cyta Therapeutics Inc.DiscoveryBioMed, Inc.ETX Pharma, IncMAX BioPharma, Inc.Relburn-Metabolomics, Inc.SinoVeda Canada Inc.ViaCyte, Inc. Viking Therapeutics, Inc. (NASDAQ:

VKTX)

MULTIPLE THERAPEUTICSColby Pharmaceutical Company Epigen Biosciences, Inc.ImCyseQuanterix CorporationSorrento Therapeutics, Inc. (NASDAQ:

SRNE)

NON-PROFIT/ADVOCACY ORGANIZATION

JDRFPancreatic Cancer Action NetworkSt. Baldrick’s FoundationTourette Association of America, Inc.

ONCOLOGY7 Hills Pharma LLCAvelas Biosciences, Inc.AVEO Oncology (NASDAQ: AVEO)Avidity Biosciences LLCBiosortia Pharmaceuticals, Inc.Boston Immune Technologies and

TherapeuticsCalithera Biosciences (NASDAQ: CALA)Cellectar Biosciences, Inc (NASDAQ:

CLRB)

CENTROSE LLCChrysalis Therapeutics, Inc.ConcentrxCritical Outcome Technologies Inc. (TSXV

and OTCQB: COT and OTCQF)Curtana Pharmaceuticals, Inc.CytoSavvyGenomatica (spin-out

company TerraMed Therapeutics)F-starGradalis, Inc.Helix BioPharma (TSX: HBP)Intezyne Technologies, Inc.Kadmon Holdings, Inc (NYSE: KDMN)Karus Therapeutics LtdKaryopharm Therapeutics (NASDAQ:

KPTI)Lexi Pharma Inc. MabVax Therapeutics Holdings, Inc.

(OTCQB: MBVX)MetaStat, Inc.MultiVir IncNuvOx Pharma, LLCOn Target LaboratoriesOncolytics Biotech Inc. (OTCQX / TSX:

ONCYF / ONC)Onconova Therapeutics, Inc. (NASDAQ:

ONTX)Oncternal Therapeutics, Inc.Onxeo (Euronext (Paris - France) -

NASDAQ (Copenhagen - Denmark): ONX)

Oxford BioTherapeuticsProNAi Therapeutics IncSalarius PharmaceuticalsSIWA CorporationSophiris Bio Inc. (NASDAQ: SPHS)Soricimed Biopharma Inc.SupremeCure Pharma Inc.Susavion Biosciences, Inc.Sutro Biopharma Inc.Verthermia, Inc.

ORPHAN/RARE DISEASESAMP PharmaceuticalsAngiocrine Bioscience, Inc.Catalyst Pharmaceuticals, Inc. (NASDAQ:

CPRX)Centogene AGMast Therapeutics, Inc. (NYSE MKT:

MSTX)Ocera Therapeutics, Inc. (NASDAQ:

OCRX)PhaseRx, Inc. (NASDAQ: PZRX)

OTHERAboGenChimera BioTechnology, Inc.Evestra, Inc.Floragraph LLCSingle Cell Technology, Inc.Teewinot Life Sciences Corporation

PAIN MANAGEMENTProove Biosciences Inc.

PLATFORM FOR THERAPEUTICSASDERA Kiromic, Inc.RXi Pharmaceuticals Corporation

(NASDAQ: RXII)Symic Biomedical, Inc.twoXARXcell BioscienceszPREDICTA, Inc.

REGENERATIVE MEDICINEBioTime, Inc. (NYSE: BTX) BioTime, Inc.

(NYSE: BTX)Capricor Therapeutics, Inc. (NASDAQ:

CAPR)Mesentech Inc

REPRODUCTIVE/SEXUAL HEALTHApricus Biosciences, Inc. Evofem BiosciencesViramal

RESPIRATORYAttenua, Inc hVIVO plc (AIM: HVO)OrPro Therapeutics IncPatara Pharma, LLCRespireRx Pharmaceuticals Inc.

(OTC QB: RSPI)

TOOLS/DRUg DEVELOPMENT SUPPORT TECHNOLOgY

Anven AlzDx Inc.Correlia Biosystems, Inc.Digital Bioanalytics, Inc.Jiangsu Atom Bioscience and

Pharmaceutical Co., Ltd.Nortis, Inc.

VACCINESAlleCures Inc Adjuvance TechnologiesImmunovaccine Inc. (IMV: IMV)

-12-

Registration

BIO offers a number of ways for conference attendees to save money on their registration fees. Discounted rates apply to the following:

Biotech companies that have raised less than $25 million in capital.

Presenting companies bringing three or more attendees.

Companies bringing more than two employees.

Corporations or other entities that use biotechnology or related technologies for research and development of products or information.

Academic institutions.

Qualified institutional and venture investors are eligible for complimentary registration.

Hotel/Venue InformationWestin St. Francis Hotel335 Powell StreetSan Francisco, California 94102Book your room today to also receive the discounted room rate. Reservation requests are based on availability, space is limited.

Register today at bio.org/investorforum

3

3

3

3

3

2016 SponsorsSupporting Bank SponsorsRegional Co-Hosts

Industry Supporter

BIO Double Helix Sponsors

BIO Helix Sponsors

Conference Sponsors

Contact us today for a tailored sponsorship package that will meet your business objectives. Please contact:Liz Colangelo at lcolangelo@bio.org and (202) 962-6656.For more information on BIO sponsorships, please visit www.bio.org/sponsor

Join the conversation:Learn more about Biotechnology at bio.orgEngage with the Biotech Community at BIOtech-NOW.orgFollow us on Twitter @bio1x1 and tweet with #BIF16Become a fan on Facebook (facebook.com/IAmBiotech)